Enhanced platelet turnover, estimated by reticulated platelets, may play a key role in the pathogenesis of atherothrombotic diseases and contribute to high on-treatment platelet reactivity.
Answers are grounded in this paper and cite their sources.
Reticulated platelets may aid prognostication in atherothrombosis; leaves open whether targeting turnover improves outcomes.
Platelets are key players in atherothrombosis. Antiplatelet therapy comprising aspirin alone or with P2Y12-inhibitors are effective for prevention of atherothrombotic complications. However, there is interindividual variability in the response to antiplatelet drugs, leaving some patients at increased risk of recurrent atherothrombotic events. Several risk factors associated with high on-treatment platelet reactivity (HTPR), including elevated platelet turnover, have been identified. Platelet turnover is adequately estimated from the fraction of reticulated platelets. Reticulated platelets are young platelets, characterised by residual messenger RNA. They are larger, haemostatically more active and there is evidence that platelet turnover is a causal and prognostic factor in atherothrombotic disease. Whether platelet turnover per se represents a key factor in pathogenesis, progression and prognosis of atherothrombotic diseases (with focus on acute coronary syndromes) or whether it merely facilitates insufficient platelet inhibition will be discussed in this state-of-the art review.
No takes yet. Share an insight, caveat, or question.
Gruber et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: